Michael Benkowitz - Mar 10, 2025 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Role
PRESIDENT AND COO
Signature
/s/ John S. Hess, Jr. under Power of Attorney
Stock symbol
UTHR
Transactions as of
Mar 10, 2025
Transactions value $
-$418,184
Form type
4
Date filed
3/11/2025, 04:30 PM
Previous filing
Mar 4, 2025
Next filing
Sep 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UTHR Common Stock Options Exercise $222K +2K $111.00 2K Mar 10, 2025 by Trust F1, F2
transaction UTHR Common Stock Sale -$60.6K -193 -9.65% $313.93 1.81K Mar 10, 2025 by Trust F1, F2
transaction UTHR Common Stock Sale -$63.4K -200 -11.07% $317.11 1.61K Mar 10, 2025 by Trust F1, F2, F3
transaction UTHR Common Stock Sale -$101K -316 -19.66% $319.35 1.29K Mar 10, 2025 by Trust F1, F2, F4
transaction UTHR Common Stock Sale -$171K -533 -41.29% $320.57 758 Mar 10, 2025 by Trust F1, F2, F5
transaction UTHR Common Stock Sale -$115K -358 -47.23% $321.62 400 Mar 10, 2025 by Trust F1, F2, F6
transaction UTHR Common Stock Sale -$96.9K -300 -75% $322.86 100 Mar 10, 2025 by Trust F1, F2, F7
transaction UTHR Common Stock Sale -$32.4K -100 -100% $323.99 0 Mar 10, 2025 by Trust F1, F2
holding UTHR Common Stock 2.65K Mar 10, 2025 Direct F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UTHR Stock Options Options Exercise $0 -2K -100% $0.00 0 Mar 10, 2025 Common Stock 2K $111.00 by Trust F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024.
F2 Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
F3 This transaction was executed in multiple trades at prices ranging from $316.76 to $317.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $319.09 to $320.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $320.09 to $320.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $321.10 to $321.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $322.285 to $323.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 Includes 71 shares of common stock acquired on March 4, 2025 under the United Therapeutics Employee Stock Purchase Plan.